A multi-centre, open label, single arm, 32-week treatment study in subjects with severe eosinophilic asthma not optimally controlled with current omalizumab treatment who are switched from omalizumab to mepolizumab 100 mg subcutaneous-the OSMO study

Administered By

Awarded By

Contributors

Start/End

  • March 1, 2016 - December 18, 2017